drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01234 | DB09048 | 1,220 | 555 | [
"DDInter513",
"DDInter1284"
] | Dexamethasone | Netupitant | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Moderate | 1 | [
[
[
1220,
24,
555
]
],
[
[
1220,
63,
1101
],
[
1101,
23,
555
]
],
[
[
1220,
25,
466
],
[
466,
62,
555
]
],
[
[
1220,
24,
384
],
[
384,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Dexamethasone may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide ma... |
DB01132 | DB01267 | 1,130 | 519 | [
"DDInter1472",
"DDInter1381"
] | Pioglitazone | Paliperidone | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
1130,
24,
519
]
],
[
[
1130,
63,
1664
],
[
1664,
1,
519
]
],
[
[
1130,
24,
924
],
[
924,
1,
519
]
],
[
[
1130,
6,
12523
],
[
12523,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone... |
DB00451 | DB08938 | 542 | 1,384 | [
"DDInter1064",
"DDInter1112"
] | Levothyroxine | Magaldrate | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
542,
24,
1384
]
],
[
[
542,
23,
699
],
[
699,
23,
1384
]
],
[
[
542,
62,
461
],
[
461,
23,
1384
]
],
[
[
542,
63,
1252
],
[
1252,
... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nadolol"
],
[
... | Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Nadolol and Nadolol may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Timolol and Timolol may cau... |
DB00704 | DB04868 | 267 | 478 | [
"DDInter1263",
"DDInter1293"
] | Naltrexone | Nilotinib | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
267,
24,
478
]
],
[
[
267,
24,
1468
],
[
1468,
63,
478
]
],
[
[
267,
6,
15705
],
[
15705,
45,
478
]
],
[
[
267,
18,
8733
],
[
8733,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Naltrexone (Compound) binds UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Nilotinib (Compound)
Naltrexone (Compound) ... |
DB00888 | DB01004 | 1,001 | 563 | [
"DDInter1133",
"DDInter806"
] | Mechlorethamine | Ganciclovir | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
1001,
24,
563
]
],
[
[
1001,
24,
248
],
[
248,
40,
563
]
],
[
[
1001,
21,
29169
],
[
29169,
60,
563
]
],
[
[
1001,
25,
770
],
[
770,
... | [
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
... | Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Mechlorethamine (Compound) causes Tinnitus (Side Effect) and Tinnitus (Side Effect) is caused by Ganciclovir (Compound)
Mechlorethamine may lead t... |
DB06616 | DB11718 | 594 | 927 | [
"DDInter224",
"DDInter640"
] | Bosutinib | Encorafenib | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
594,
24,
927
]
],
[
[
594,
62,
112
],
[
112,
23,
927
]
],
[
[
594,
24,
720
],
[
720,
24,
927
]
],
[
[
594,
63,
372
],
[
372,
24,... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Bosutinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Bosutinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mine... |
DB00196 | DB00978 | 600 | 739 | [
"DDInter743",
"DDInter1084"
] | Fluconazole | Lomefloxacin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Moderate | 1 | [
[
[
600,
24,
739
]
],
[
[
600,
25,
945
],
[
945,
40,
739
]
],
[
[
600,
24,
872
],
[
872,
40,
739
]
],
[
[
600,
25,
1176
],
[
1176,
1... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Spar... | Fluconazole may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Lomefloxacin (Compound)
F... |
DB00365 | DB00531 | 839 | 450 | [
"DDInter842",
"DDInter456"
] | Grepafloxacin | Cyclophosphamide | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Minor | 0 | [
[
[
839,
23,
450
]
],
[
[
839,
23,
1001
],
[
1001,
40,
450
]
],
[
[
839,
62,
377
],
[
377,
24,
450
]
],
[
[
839,
24,
1017
],
[
1017,
... | [
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mechlorethamine"
... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine and Mechlorethamine (Compound) resembles Cyclophosphamide (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Mitomycin and Mitomycin may cause a moderate intera... |
DB00019 | DB01229 | 1,257 | 973 | [
"DDInter1405",
"DDInter1378"
] | Pegfilgrastim | Paclitaxel (protein-bound) | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
1257,
24,
973
]
],
[
[
1257,
24,
310
],
[
310,
63,
973
]
],
[
[
1257,
24,
134
],
[
134,
24,
973
]
],
[
[
1257,
63,
491
],
[
491,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Pe... |
DB00987 | DB05528 | 1,224 | 1,070 | [
"DDInter460",
"DDInter1228"
] | Cytarabine | Mipomersen | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
1224,
25,
1070
]
],
[
[
1224,
63,
552
],
[
552,
25,
1070
]
],
[
[
1224,
64,
581
],
[
581,
25,
1070
]
],
[
[
1224,
24,
384
],
[
384,
... | [
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine... | Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Mipomersen
Cytarabine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life ... |
DB00280 | DB08897 | 494 | 1,429 | [
"DDInter575",
"DDInter22"
] | Disopyramide | Aclidinium | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
494,
24,
1429
]
],
[
[
494,
63,
352
],
[
352,
24,
1429
]
],
[
[
494,
24,
1511
],
[
1511,
24,
1429
]
],
[
[
494,
6,
4304
],
[
4304,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepen... |
DB00635 | DB01211 | 1,573 | 609 | [
"DDInter1515",
"DDInter393"
] | Prednisone | Clarithromycin | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
1573,
24,
609
]
],
[
[
1573,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1573,
7,
7248
],
[
7248,
46,
609
]
],
[
[
1573,
21,
28759
],
[
28759,... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Prednisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Prednisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Prednisone (Compound) upregulates RPP38 (Gene) and RPP38 (Gene) is upregulated by Clarithromycin (Compound)
Prednisone (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) i... |
DB00630 | DB00927 | 1,485 | 1,559 | [
"DDInter42",
"DDInter712"
] | Alendronic acid | Famotidine | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Minor | 0 | [
[
[
1485,
23,
1559
]
],
[
[
1485,
7,
3492
],
[
3492,
46,
1559
]
],
[
[
1485,
21,
32516
],
[
32516,
60,
1559
]
],
[
[
1485,
24,
1384
],
[
1... | [
[
[
"Alendronic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Alendronic acid",
"{u} (Compound) upregulates {v} (Gene)",
"E2F2"
],
[
"E2F2",
"{u} (Gene) is upregulated by ... | Alendronic acid (Compound) upregulates E2F2 (Gene) and E2F2 (Gene) is upregulated by Famotidine (Compound)
Alendronic acid (Compound) causes Erosive oesophagitis (Side Effect) and Erosive oesophagitis (Side Effect) is caused by Famotidine (Compound)
Alendronic acid may cause a moderate interaction that could exacerbate... |
DB00594 | DB11921 | 863 | 1,019 | [
"DDInter68",
"DDInter492"
] | Amiloride | Deflazacort | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
863,
24,
1019
]
],
[
[
863,
63,
355
],
[
355,
24,
1019
]
],
[
[
863,
24,
286
],
[
286,
24,
1019
]
],
[
[
863,
24,
1220
],
[
1220,
... | [
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
... | Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and ... |
DB00374 | DB01138 | 1,061 | 804 | [
"DDInter1852",
"DDInter1726"
] | Treprostinil | Sulfinpyrazone | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
1061,
24,
804
]
],
[
[
1061,
24,
998
],
[
998,
1,
804
]
],
[
[
1061,
6,
6017
],
[
6017,
45,
804
]
],
[
[
1061,
18,
1954
],
[
1954,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Treprostinil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sulfinpyrazone (Compound)
Treprostinil (Compound) downregulates COG2 (Ge... |
DB00382 | DB00704 | 62 | 267 | [
"DDInter1734",
"DDInter1263"
] | Tacrine | Naltrexone | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
62,
24,
267
]
],
[
[
62,
24,
850
],
[
850,
63,
267
]
],
[
[
62,
63,
912
],
[
912,
24,
267
]
],
[
[
62,
24,
1555
],
[
1555,
24,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Interfero... |
DB00295 | DB00782 | 475 | 1,123 | [
"DDInter1244",
"DDInter1535"
] | Morphine | Propantheline | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
475,
24,
1123
]
],
[
[
475,
21,
28898
],
[
28898,
60,
1123
]
],
[
[
475,
24,
359
],
[
359,
62,
1123
]
],
[
[
475,
24,
323
],
[
323,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is... | Morphine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Propantheline (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide may cause a minor interaction that can limit clinical effects when taken w... |
DB00662 | DB01267 | 717 | 519 | [
"DDInter1873",
"DDInter1381"
] | Trimethobenzamide | Paliperidone | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
717,
24,
519
]
],
[
[
717,
24,
1664
],
[
1664,
1,
519
]
],
[
[
717,
21,
28826
],
[
28826,
60,
519
]
],
[
[
717,
63,
1233
],
[
1233,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Trimethobenzamide (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Paliperidone (Compound)
Trimethobenzamide may caus... |
DB00361 | DB10795 | 134 | 221 | [
"DDInter1939",
"DDInter1486"
] | Vinorelbine | Poliovirus type 1 antigen (formaldehyde inactivated) | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
134,
24,
221
]
],
[
[
134,
24,
36
],
[
36,
24,
221
]
],
[
[
134,
64,
581
],
[
581,
24,
221
]
],
[
[
134,
63,
599
],
[
599,
24,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken w... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Vinorelbine may lead to a major life threatening interaction when taken w... |
DB01017 | DB01324 | 1,669 | 178 | [
"DDInter1224",
"DDInter1490"
] | Minocycline | Polythiazide | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Minor | 0 | [
[
[
1669,
23,
178
]
],
[
[
1669,
23,
674
],
[
674,
40,
178
]
],
[
[
1669,
62,
504
],
[
504,
40,
178
]
],
[
[
1669,
40,
964
],
[
964,
... | [
[
[
"Minocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
]
],
[
[
"Minocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
],
... | Minocycline may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Minocycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound... |
DB09043 | DB14509 | 135 | 1,399 | [
"DDInter36",
"DDInter1081"
] | Albiglutide | Lithium carbonate | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
135,
24,
1399
]
],
[
[
135,
63,
874
],
[
874,
23,
1399
]
],
[
[
135,
63,
820
],
[
820,
24,
1399
]
],
[
[
135,
24,
144
],
[
144,
... | [
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
]... | Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine ... |
DB01259 | DB06414 | 392 | 655 | [
"DDInter1024",
"DDInter703"
] | Lapatinib | Etravirine | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
392,
24,
655
]
],
[
[
392,
24,
786
],
[
786,
40,
655
]
],
[
[
392,
6,
4973
],
[
4973,
45,
655
]
],
[
[
392,
21,
28723
],
[
28723,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine (Compound) resembles Etravirine (Compound)
Lapatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Lapatinib (Compound) causes Malnutrition (Side Effect) and Malnutrit... |
DB01344 | DB11189 | 1,231 | 1,333 | [
"DDInter1830",
"DDInter1117"
] | Tolevamer | Magnesium glycinate | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Magnesium glycinate is a magnesium salt of glycine that is available as dietary supplements as a source of magnesium. It is used in the treatment of magnesium deficiency. | Moderate | 1 | [
[
[
1231,
24,
1333
]
],
[
[
1231,
25,
286
],
[
286,
24,
1333
]
],
[
[
1231,
25,
286
],
[
286,
24,
460
],
[
460,
24,
1333
]
],
[
[
1231,
... | [
[
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium glycinate"
]
],
[
[
"Tolevamer",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium hydroxide"
],
[
... | Tolevamer may lead to a major life threatening interaction when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Tolevamer may lead to a major life threatening interaction when taken with Magnesium hydroxide and Ma... |
DB06402 | DB09080 | 1,079 | 144 | [
"DDInter1756",
"DDInter1331"
] | Telavancin | Olodaterol | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1079,
24,
144
]
],
[
[
1079,
25,
1011
],
[
1011,
24,
144
]
],
[
[
1079,
64,
11
],
[
11,
24,
144
]
],
[
[
1079,
63,
543
],
[
543,
... | [
[
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Telavancin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod... | Telavancin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Telavancin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate inte... |
DB00928 | DB11817 | 1,426 | 1,259 | [
"DDInter148",
"DDInter165"
] | Azacitidine | Baricitinib | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1426,
25,
1259
]
],
[
[
1426,
63,
1461
],
[
1461,
23,
1259
]
],
[
[
1426,
24,
949
],
[
949,
24,
1259
]
],
[
[
1426,
24,
1129
],
[
1129... | [
[
[
"Azacitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani tox... |
DB01403 | DB09472 | 9 | 1,383 | [
"DDInter1175",
"DDInter1693"
] | Methotrimeprazine | Sodium sulfate | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
9,
24,
1383
]
],
[
[
9,
63,
609
],
[
609,
24,
1383
]
],
[
[
9,
1,
146
],
[
146,
24,
1383
]
],
[
[
9,
64,
1311
],
[
1311,
24,
... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithro... | Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Methotrimeprazine (Compound) resembles Propiomazine (Compound) and Propiomazine may cause a m... |
DB00529 | DB01129 | 789 | 379 | [
"DDInter779",
"DDInter1559"
] | Foscarnet | Rabeprazole | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Moderate | 1 | [
[
[
789,
24,
379
]
],
[
[
789,
63,
1215
],
[
1215,
40,
379
]
],
[
[
789,
24,
660
],
[
660,
1,
379
]
],
[
[
789,
63,
837
],
[
837,
1,... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
... | Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Rabeprazole (Compound)
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Rabeprazole (Co... |
DB00262 | DB01206 | 552 | 37 | [
"DDInter302",
"DDInter1086"
] | Carmustine | Lomustine | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
552,
35,
37
]
],
[
[
552,
5,
11613
],
[
11613,
44,
37
]
],
[
[
552,
54,
19138
],
[
19138,
15,
37
]
],
[
[
552,
21,
28675
],
[
28675,
... | [
[
[
"Carmustine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Carmustine",
"{u} (Compound) treats {v} (Disease)",
"brain cancer"
],
[
"br... | Carmustine (Compound) resembles Lomustine (Compound) and
Carmustine (Compound) treats brain cancer (Disease) and brain cancer (Disease) is treated by Lomustine (Compound)
Carmustine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Lomustine (Comp... |
DB00635 | DB01265 | 1,573 | 1,477 | [
"DDInter1515",
"DDInter1757"
] | Prednisone | Telbivudine | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Moderate | 1 | [
[
[
1573,
24,
1477
]
],
[
[
1573,
63,
139
],
[
139,
1,
1477
]
],
[
[
1573,
21,
28745
],
[
28745,
60,
1477
]
],
[
[
1573,
1,
1220
],
[
1220... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Telbivudine (Compound)
Prednisone (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Telbivudine (Compound)
Prednisone (Compou... |
DB00520 | DB01234 | 1,358 | 1,220 | [
"DDInter306",
"DDInter513"
] | Caspofungin | Dexamethasone | Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of th... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Major | 2 | [
[
[
1358,
25,
1220
]
],
[
[
1358,
6,
8374
],
[
8374,
45,
1220
]
],
[
[
1358,
21,
28835
],
[
28835,
60,
1220
]
],
[
[
1358,
63,
1101
],
[
1... | [
[
[
"Caspofungin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
]
],
[
[
"Caspofungin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"De... | Caspofungin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dexamethasone (Compound)
Caspofungin (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Dexamethasone (Compound)
Caspofungin may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB05273 | DB06704 | 507 | 247 | [
"DDInter1638",
"DDInter952"
] | Samarium (153Sm) lexidronam | Iobenguane (I-131) | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
507,
25,
247
]
],
[
[
507,
63,
563
],
[
563,
24,
247
]
],
[
[
507,
64,
695
],
[
695,
25,
247
]
],
[
[
507,
63,
563
],
[
563,
21,... | [
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclo... | Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Iobenguane
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00241 | DB04868 | 288 | 478 | [
"DDInter257",
"DDInter1293"
] | Butalbital | Nilotinib | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
288,
24,
478
]
],
[
[
288,
24,
1468
],
[
1468,
63,
478
]
],
[
[
288,
24,
1135
],
[
1135,
62,
478
]
],
[
[
288,
24,
112
],
[
112,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol ... |
DB00224 | DB11921 | 215 | 1,019 | [
"DDInter917",
"DDInter492"
] | Indinavir | Deflazacort | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
215,
25,
1019
]
],
[
[
215,
24,
959
],
[
959,
24,
1019
]
],
[
[
215,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
215,
25,
629
],
[
629,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib ... |
DB04868 | DB09080 | 478 | 144 | [
"DDInter1293",
"DDInter1331"
] | Nilotinib | Olodaterol | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
478,
24,
144
]
],
[
[
478,
62,
1247
],
[
1247,
23,
144
]
],
[
[
478,
64,
956
],
[
956,
24,
144
]
],
[
[
478,
25,
1011
],
[
1011,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Nilotinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Nilotinib may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin ma... |
DB00277 | DB01135 | 1,031 | 648 | [
"DDInter1791",
"DDInter590"
] | Theophylline | Doxacurium | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration. | Moderate | 1 | [
[
[
1031,
24,
648
]
],
[
[
1031,
24,
1319
],
[
1319,
40,
648
]
],
[
[
1031,
24,
1194
],
[
1194,
23,
648
]
],
[
[
1031,
24,
251
],
[
251,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxacurium"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mivacurium"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Mivacurium and Mivacurium (Compound) resembles Doxacurium (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can ... |
DB09268 | DB11640 | 1,662 | 1,267 | [
"DDInter1464",
"DDInter64"
] | Picosulfuric acid | Amifampridine | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations . It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscul... | Moderate | 1 | [
[
[
1662,
24,
1267
]
],
[
[
1662,
63,
1220
],
[
1220,
24,
1267
]
],
[
[
1662,
24,
407
],
[
407,
24,
1267
]
],
[
[
1662,
24,
913
],
[
913,
... | [
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethas... | Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00307 | DB00559 | 1,101 | 152 | [
"DDInter202",
"DDInter223"
] | Bexarotene | Bosentan | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Minor | 0 | [
[
[
1101,
23,
152
]
],
[
[
1101,
6,
6017
],
[
6017,
45,
152
]
],
[
[
1101,
21,
29059
],
[
29059,
60,
152
]
],
[
[
1101,
62,
608
],
[
608,
... | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bosentan"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Bexarotene (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bosentan (Compound)
Bexarotene (Compound) causes Lethargy (Side Effect) and Lethargy (Side Effect) is caused by Bosentan (Compound)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may... |
DB00526 | DB00911 | 1,555 | 458 | [
"DDInter1355",
"DDInter1811"
] | Oxaliplatin | Tinidazole | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Moderate | 1 | [
[
[
1555,
24,
458
]
],
[
[
1555,
24,
112
],
[
112,
1,
458
]
],
[
[
1555,
63,
238
],
[
238,
24,
458
]
],
[
[
1555,
24,
310
],
[
310,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole (Compound) resembles Tinidazole (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol and Ethambutol may cause a moderate interaction th... |
DB00295 | DB01244 | 475 | 762 | [
"DDInter1244",
"DDInter192"
] | Morphine | Bepridil | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Moderate | 1 | [
[
[
475,
24,
762
]
],
[
[
475,
24,
1376
],
[
1376,
24,
762
]
],
[
[
475,
25,
704
],
[
704,
1,
762
]
],
[
[
475,
24,
832
],
[
832,
40... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Morphine may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl (Compound)... |
DB00334 | DB00983 | 867 | 480 | [
"DDInter1326",
"DDInter776"
] | Olanzapine | Formoterol | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
867,
24,
480
]
],
[
[
867,
24,
1148
],
[
1148,
63,
480
]
],
[
[
867,
6,
6017
],
[
6017,
45,
480
]
],
[
[
867,
24,
1424
],
[
1424,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Olanzapine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Formoterol (Compound)
Olanzapine may... |
DB00358 | DB01023 | 1,010 | 409 | [
"DDInter1140",
"DDInter716"
] | Mefloquine | Felodipine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Moderate | 1 | [
[
[
1010,
24,
409
]
],
[
[
1010,
24,
376
],
[
376,
40,
409
]
],
[
[
1010,
63,
1428
],
[
1428,
1,
409
]
],
[
[
1010,
24,
854
],
[
854,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) resembles Felodipine (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Felodipine (Compound)
... |
DB00307 | DB00813 | 1,101 | 704 | [
"DDInter202",
"DDInter722"
] | Bexarotene | Fentanyl | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Moderate | 1 | [
[
[
1101,
24,
704
]
],
[
[
1101,
24,
307
],
[
307,
1,
704
]
],
[
[
1101,
24,
194
],
[
194,
40,
704
]
],
[
[
1101,
23,
998
],
[
998,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil (Compound) resembles Fentanyl (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Fentanyl (Compound)
Bexa... |
DB08881 | DB12010 | 868 | 214 | [
"DDInter1925",
"DDInter785"
] | Vemurafenib | Fostamatinib | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
868,
24,
214
]
],
[
[
868,
24,
976
],
[
976,
24,
214
]
],
[
[
868,
63,
723
],
[
723,
24,
214
]
],
[
[
868,
64,
690
],
[
690,
24,... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and ... |
DB01149 | DB08875 | 851 | 1,618 | [
"DDInter1274",
"DDInter262"
] | Nefazodone | Cabozantinib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
851,
25,
1618
]
],
[
[
851,
25,
1135
],
[
1135,
62,
1618
]
],
[
[
851,
63,
723
],
[
723,
24,
1618
]
],
[
[
851,
24,
384
],
[
384,
... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Nefazodone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a ... |
DB00224 | DB00357 | 215 | 1,051 | [
"DDInter917",
"DDInter71"
] | Indinavir | Aminoglutethimide | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Moderate | 1 | [
[
[
215,
24,
1051
]
],
[
[
215,
6,
8374
],
[
8374,
45,
1051
]
],
[
[
215,
21,
28803
],
[
28803,
60,
1051
]
],
[
[
215,
24,
1411
],
[
1411,... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aminoglutethimide (Compound)
Indinavir (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Aminoglutethimide (Compound)
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide ... |
DB00370 | DB12267 | 1,251 | 1,476 | [
"DDInter1230",
"DDInter233"
] | Mirtazapine | Brigatinib | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1251,
24,
1476
]
],
[
[
1251,
24,
629
],
[
629,
24,
1476
]
],
[
[
1251,
25,
1133
],
[
1133,
24,
1476
]
],
[
[
1251,
63,
1181
],
[
1181... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Mirtazapine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may caus... |
DB01319 | DB06772 | 34 | 310 | [
"DDInter777",
"DDInter259"
] | Fosamprenavir | Cabazitaxel | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
34,
24,
310
]
],
[
[
34,
64,
973
],
[
973,
24,
310
]
],
[
[
34,
6,
8374
],
[
8374,
45,
310
]
],
[
[
34,
21,
28646
],
[
28646,
60... | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
],
[
"Pac... | Fosamprenavir may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Fosamprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cabazitaxel (Compound)
Fosamprenavir (Compound) ... |
DB05015 | DB12825 | 1,077 | 1,375 | [
"DDInter174",
"DDInter1032"
] | Belinostat | Lefamulin | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
1077,
24,
1375
]
],
[
[
1077,
25,
976
],
[
976,
24,
1375
]
],
[
[
1077,
24,
292
],
[
292,
24,
1375
]
],
[
[
1077,
25,
676
],
[
676,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitini... | Belinostat may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may cau... |
DB01764 | DB11921 | 805 | 1,019 | [
"DDInter469",
"DDInter492"
] | Dalfopristin | Deflazacort | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
805,
25,
1019
]
],
[
[
805,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
805,
24,
761
],
[
761,
24,
1019
]
],
[
[
805,
63,
629
],
[
629,
... | [
[
[
"Dalfopristin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucapa... | Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Sa... |
DB00604 | DB01166 | 1,425 | 477 | [
"DDInter385",
"DDInter379"
] | Cisapride | Cilostazol | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Major | 2 | [
[
[
1425,
25,
477
]
],
[
[
1425,
6,
8374
],
[
8374,
45,
477
]
],
[
[
1425,
23,
112
],
[
112,
23,
477
]
],
[
[
1425,
24,
126
],
[
126,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cilostazo... | Cisapride (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Cisapride may caus... |
DB00163 | DB00987 | 1,461 | 1,224 | [
"DDInter1943",
"DDInter460"
] | Vitamin E | Cytarabine | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Moderate | 1 | [
[
[
1461,
24,
1224
]
],
[
[
1461,
24,
1426
],
[
1426,
1,
1224
]
],
[
[
1461,
24,
322
],
[
322,
24,
1224
]
],
[
[
1461,
62,
66
],
[
66,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azacitidine"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Azacitidine and Azacitidine (Compound) resembles Cytarabine (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could... |
DB00524 | DB00731 | 811 | 1,144 | [
"DDInter1199",
"DDInter1269"
] | Metolazone | Nateglinide | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
811,
24,
1144
]
],
[
[
811,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
811,
24,
1042
],
[
1042,
63,
1144
]
],
[
[
811,
24,
870
],
[
870,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Metolazone",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is c... | Metolazone (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken w... |
DB06410 | DB12147 | 1,196 | 241 | [
"DDInter595",
"DDInter661"
] | Doxercalciferol | Erdafitinib | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Major | 2 | [
[
[
1196,
25,
241
]
],
[
[
1196,
24,
1619
],
[
1619,
63,
241
]
],
[
[
1196,
24,
286
],
[
286,
25,
241
]
],
[
[
1196,
63,
965
],
[
965,
... | [
[
[
"Doxercalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"... | Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hy... |
DB00197 | DB00860 | 1,324 | 891 | [
"DDInter1881",
"DDInter1513"
] | Troglitazone | Prednisolone | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1324,
24,
891
]
],
[
[
1324,
24,
989
],
[
989,
1,
891
]
],
[
[
1324,
24,
175
],
[
175,
40,
891
]
],
[
[
1324,
24,
1561
],
[
1561,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Progesterone"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Prednisolone (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Predni... |
DB00087 | DB00812 | 599 | 998 | [
"DDInter41",
"DDInter1451"
] | Alemtuzumab | Phenylbutazone | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Moderate | 1 | [
[
[
599,
24,
998
]
],
[
[
599,
24,
168
],
[
168,
23,
998
]
],
[
[
599,
24,
594
],
[
594,
63,
998
]
],
[
[
599,
24,
251
],
[
251,
24,... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Phenylbutazone
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bos... |
DB00559 | DB00673 | 152 | 723 | [
"DDInter223",
"DDInter112"
] | Bosentan | Aprepitant | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
152,
24,
723
]
],
[
[
152,
6,
8374
],
[
8374,
45,
723
]
],
[
[
152,
21,
28890
],
[
28890,
60,
723
]
],
[
[
152,
24,
222
],
[
222,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aprepitant (Compound)
Bosentan (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Aprepitant (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with S... |
DB00593 | DB14724 | 1,464 | 48 | [
"DDInter695",
"DDInter634"
] | Ethosuximide | Emapalumab | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority... | Moderate | 1 | [
[
[
1464,
24,
48
]
],
[
[
1464,
6,
6799
],
[
6799,
45,
1463
],
[
1463,
24,
48
]
],
[
[
1464,
21,
28722
],
[
28722,
60,
1463
],
[
1463,
2... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Ethosuximide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compoun... | Ethosuximide (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Ethosuximide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lovastatin (Compound) and Lo... |
DB00321 | DB00804 | 21 | 1,507 | [
"DDInter78",
"DDInter543"
] | Amitriptyline | Dicyclomine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
21,
24,
1507
]
],
[
[
21,
6,
2720
],
[
2720,
45,
1507
]
],
[
[
21,
21,
28817
],
[
28817,
60,
1507
]
],
[
[
21,
35,
1594
],
[
1594,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compou... | Amitriptyline (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Dicyclomine (Compound)
Amitriptyline (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Dicyclomine (Compound)
Amitriptyline (Compound) resembles Doxylamine (Compound) and Amitriptyline may cause a moderat... |
DB00559 | DB06772 | 152 | 310 | [
"DDInter223",
"DDInter259"
] | Bosentan | Cabazitaxel | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
152,
24,
310
]
],
[
[
152,
24,
973
],
[
973,
24,
310
]
],
[
[
152,
6,
8374
],
[
8374,
45,
310
]
],
[
[
152,
21,
28894
],
[
28894,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cabazitaxel (Compound)
Bosentan (Compound) ... |
DB06603 | DB09082 | 39 | 659 | [
"DDInter1387",
"DDInter1934"
] | Panobinostat | Vilanterol | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
39,
24,
659
]
],
[
[
39,
63,
1220
],
[
1220,
23,
659
]
],
[
[
39,
64,
1570
],
[
1570,
24,
659
]
],
[
[
39,
25,
927
],
[
927,
63,... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Panobinostat may lead to a major life threatening interaction when taken with Azithromycin and Azithromyci... |
DB08868 | DB14443 | 1,011 | 987 | [
"DDInter737",
"DDInter1931"
] | Fingolimod | Vibrio cholerae CVD 103-HgR strain live antigen | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1011,
24,
987
]
],
[
[
1011,
25,
1480
],
[
1480,
24,
987
]
],
[
[
1011,
64,
141
],
[
141,
24,
987
]
],
[
[
1011,
25,
994
],
[
994,
... | [
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazo... | Fingolimod may lead to a major life threatening interaction when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Fingolimod may lead to a major life threatening interaction when taken with Floxuridine and Fl... |
DB00208 | DB08938 | 1,018 | 1,384 | [
"DDInter1804",
"DDInter1112"
] | Ticlopidine | Magaldrate | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
1018,
23,
1384
]
],
[
[
1018,
23,
167
],
[
167,
23,
1384
]
],
[
[
1018,
25,
684
],
[
684,
23,
1384
]
],
[
[
1018,
24,
752
],
[
752,
... | [
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrocortisone"
],
[
... | Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Ticlopidine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine ... |
DB00023 | DB00533 | 305 | 1,416 | [
"DDInter127",
"DDInter1613"
] | Asparaginase Escherichia coli | Rofecoxib | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Moderate | 1 | [
[
[
305,
24,
1416
]
],
[
[
305,
24,
1409
],
[
1409,
63,
1416
]
],
[
[
305,
24,
912
],
[
912,
24,
1416
]
],
[
[
305,
25,
1510
],
[
1510,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when... |
DB00014 | DB01142 | 521 | 1,264 | [
"DDInter839",
"DDInter593"
] | Goserelin | Doxepin | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
521,
24,
1264
]
],
[
[
521,
24,
508
],
[
508,
24,
1264
]
],
[
[
521,
21,
29226
],
[
29226,
60,
1264
]
],
[
[
521,
23,
112
],
[
112,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"P... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Goserelin (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Doxepin (Compound)
Gosere... |
DB00384 | DB09112 | 1,275 | 1,455 | [
"DDInter1859",
"DDInter1306"
] | Triamterene | Nitrous acid | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
1275,
24,
1455
]
],
[
[
1275,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
1275,
24,
433
],
[
433,
63,
1455
]
],
[
[
1275,
63,
1061
],
[
1061... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Ertuglifloz... |
DB00771 | DB01019 | 262 | 427 | [
"DDInter397",
"DDInter199"
] | Clidinium | Bethanechol | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Bethanechol is a synthetic ester that was initially synthesized in 1935.[A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous system is necessary.[A232905,L32539] For exampl... | Moderate | 1 | [
[
[
262,
24,
427
]
],
[
[
262,
6,
2720
],
[
2720,
45,
427
]
],
[
[
262,
63,
1442
],
[
1442,
24,
427
]
],
[
[
262,
24,
1123
],
[
1123,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bethanechol"
]
],
[
[
"Clidinium",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compound)",
... | Clidinium (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Bethanechol (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Bethanechol
Clidinium may caus... |
DB00427 | DB09118 | 1,233 | 1,580 | [
"DDInter1879",
"DDInter1711"
] | Triprolidine | Stiripentol | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
1233,
24,
1580
]
],
[
[
1233,
24,
1532
],
[
1532,
24,
1580
]
],
[
[
1233,
24,
1609
],
[
1609,
63,
1580
]
],
[
[
1233,
63,
128
],
[
128... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine an... |
DB01124 | DB11837 | 1,411 | 1,297 | [
"DDInter1828",
"DDInter1351"
] | Tolbutamide | Osilodrostat | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
1411,
24,
1297
]
],
[
[
1411,
63,
1247
],
[
1247,
23,
1297
]
],
[
[
1411,
24,
623
],
[
623,
24,
1297
]
],
[
[
1411,
63,
401
],
[
401,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
]... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Quetiap... |
DB00741 | DB08899 | 167 | 129 | [
"DDInter885",
"DDInter649"
] | Hydrocortisone | Enzalutamide | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
167,
24,
129
]
],
[
[
167,
6,
8374
],
[
8374,
45,
129
]
],
[
[
167,
21,
28703
],
[
28703,
60,
129
]
],
[
[
167,
63,
312
],
[
312,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (C... | Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Hydrocortisone (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Epler... |
DB00675 | DB01234 | 888 | 1,220 | [
"DDInter1744",
"DDInter513"
] | Tamoxifen | Dexamethasone | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
888,
24,
1220
]
],
[
[
888,
6,
21998
],
[
21998,
45,
1220
]
],
[
[
888,
7,
3163
],
[
3163,
46,
1220
]
],
[
[
888,
18,
6317
],
[
6317,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound ... | Tamoxifen (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Dexamethasone (Compound)
Tamoxifen (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Dexamethasone (Compound)
Tamoxifen (Compound) downregulates MRPL12 (Gene) and MRPL12 (Gene) is upregulated by Dexamethaso... |
DB01177 | DB08895 | 77 | 976 | [
"DDInter904",
"DDInter1825"
] | Idarubicin | Tofacitinib | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
77,
25,
976
]
],
[
[
77,
63,
1461
],
[
1461,
23,
976
]
],
[
[
77,
24,
214
],
[
214,
63,
976
]
],
[
[
77,
25,
982
],
[
982,
63,
... | [
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E"... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostama... |
DB00586 | DB01099 | 1,512 | 1,272 | [
"DDInter537",
"DDInter744"
] | Diclofenac | Flucytosine | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | A fluorinated cytosine analog that is used as an antifungal agent. | Moderate | 1 | [
[
[
1512,
24,
1272
]
],
[
[
1512,
21,
29501
],
[
29501,
60,
1272
]
],
[
[
1512,
63,
311
],
[
311,
24,
1272
]
],
[
[
1512,
24,
1448
],
[
14... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Diclofenac",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatic necrosis"
],
[
"Hepatic necrosis",
"{u} (Side ... | Diclofenac (Compound) causes Hepatic necrosis (Side Effect) and Hepatic necrosis (Side Effect) is caused by Flucytosine (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when tak... |
DB01165 | DB11901 | 1,539 | 913 | [
"DDInter1325",
"DDInter107"
] | Ofloxacin | Apalutamide | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1539,
24,
913
]
],
[
[
1539,
62,
112
],
[
112,
23,
913
]
],
[
[
1539,
63,
600
],
[
600,
24,
913
]
],
[
[
1539,
24,
28
],
[
28,
2... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluc... |
DB01142 | DB01170 | 1,264 | 1,150 | [
"DDInter593",
"DDInter846"
] | Doxepin | Guanethidine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Moderate | 1 | [
[
[
1264,
24,
1150
]
],
[
[
1264,
6,
7390
],
[
7390,
45,
1150
]
],
[
[
1264,
63,
73
],
[
73,
24,
1150
]
],
[
[
1264,
74,
1376
],
[
1376,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Doxepin (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Guanethidine (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Doxepin (Compound)... |
DB03904 | DB09134 | 1,574 | 1,552 | [
"DDInter1903",
"DDInter966"
] | Urea | Ioversol | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Moderate | 1 | [
[
[
1574,
24,
1552
]
],
[
[
1574,
23,
1399
],
[
1399,
64,
1552
]
],
[
[
1574,
24,
643
],
[
643,
63,
1274
],
[
1274,
25,
1552
]
],
[
[
1574... | [
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Urea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
],
[
"Lith... | Urea may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may lead to a major life threatening interaction when taken with Ioversol
Urea may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may ... |
DB00640 | DB12141 | 1,585 | 971 | [
"DDInter31",
"DDInter817"
] | Adenosine | Gilteritinib | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1585,
24,
971
]
],
[
[
1585,
24,
485
],
[
485,
24,
971
]
],
[
[
1585,
24,
823
],
[
823,
63,
971
]
],
[
[
1585,
64,
1181
],
[
1181,
... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
... | Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and... |
DB00612 | DB00635 | 1,121 | 1,573 | [
"DDInter216",
"DDInter1515"
] | Bisoprolol | Prednisone | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
1121,
24,
1573
]
],
[
[
1121,
24,
175
],
[
175,
40,
1573
]
],
[
[
1121,
63,
251
],
[
251,
1,
1573
]
],
[
[
1121,
24,
167
],
[
167,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[... | Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone... |
DB00074 | DB11248 | 1,309 | 1,193 | [
"DDInter166",
"DDInter1965"
] | Basiliximab | Zinc gluconate | A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermenta... | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Minor | 0 | [
[
[
1309,
23,
1193
]
],
[
[
1309,
24,
1531
],
[
1531,
23,
1193
]
],
[
[
1309,
24,
270
],
[
270,
62,
1193
]
],
[
[
1309,
25,
1259
],
[
1259... | [
[
[
"Basiliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Basiliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
... | Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and... |
DB00976 | DB01142 | 1,056 | 1,264 | [
"DDInter1758",
"DDInter593"
] | Telithromycin | Doxepin | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1056,
24,
1264
]
],
[
[
1056,
24,
401
],
[
401,
24,
1264
]
],
[
[
1056,
6,
8374
],
[
8374,
45,
1264
]
],
[
[
1056,
21,
29226
],
[
2922... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Telithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxepin (Compound)
Telithromycin ... |
DB06273 | DB14444 | 980 | 151 | [
"DDInter1824",
"DDInter924"
] | Tocilizumab | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
980,
24,
151
]
],
[
[
980,
63,
66
],
[
66,
24,
151
]
],
[
[
980,
64,
1394
],
[
1394,
24,
151
]
],
[
[
980,
24,
36
],
[
36,
24,
... | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could... | Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tocilizumab may lead to a major life... |
DB00307 | DB08930 | 1,101 | 1,459 | [
"DDInter202",
"DDInter582"
] | Bexarotene | Dolutegravir | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Minor | 0 | [
[
[
1101,
23,
1459
]
],
[
[
1101,
21,
28698
],
[
28698,
60,
1459
]
],
[
[
1101,
23,
353
],
[
353,
23,
1459
]
],
[
[
1101,
25,
478
],
[
478... | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolutegravir"
]
],
[
[
"Bexarotene",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused... | Bexarotene (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Dolutegravir (Compound)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Griseofulvin and Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Doluteg... |
DB00208 | DB00939 | 1,018 | 1,338 | [
"DDInter1804",
"DDInter1135"
] | Ticlopidine | Meclofenamic acid | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
1018,
24,
1338
]
],
[
[
1018,
24,
1479
],
[
1479,
63,
1338
]
],
[
[
1018,
21,
28824
],
[
28824,
60,
1338
]
],
[
[
1018,
24,
752
],
[
7... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic ac... | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Ticlopidine (Compound) causes Jaundice cholestatic (Side Effect) and Jaundice choles... |
DB00574 | DB06605 | 121 | 1,409 | [
"DDInter717",
"DDInter108"
] | Fenfluramine | Apixaban | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
121,
24,
1409
]
],
[
[
121,
64,
109
],
[
109,
24,
1409
]
],
[
[
121,
24,
1670
],
[
1670,
63,
1409
]
],
[
[
121,
24,
1374
],
[
1374,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duloxetine"
],
[
"Duloxeti... | Fenfluramine may lead to a major life threatening interaction when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may caus... |
DB00741 | DB09268 | 167 | 1,662 | [
"DDInter885",
"DDInter1464"
] | Hydrocortisone | Picosulfuric acid | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
167,
24,
1662
]
],
[
[
167,
24,
1482
],
[
1482,
23,
1662
]
],
[
[
167,
63,
1252
],
[
1252,
23,
1662
]
],
[
[
167,
24,
1619
],
[
1619,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Digoxin an... |
DB00218 | DB09082 | 1,176 | 659 | [
"DDInter1247",
"DDInter1934"
] | Moxifloxacin | Vilanterol | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1176,
24,
659
]
],
[
[
1176,
25,
1220
],
[
1220,
23,
659
]
],
[
[
1176,
25,
1296
],
[
1296,
63,
659
]
],
[
[
1176,
25,
1069
],
[
1069,... | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dex... | Moxifloxacin may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Moxifloxacin may lead to a major life threatening interaction when taken with Insulin degludec and Insulin degludec may c... |
DB00649 | DB01041 | 231 | 770 | [
"DDInter1710",
"DDInter1789"
] | Stavudine | Thalidomide | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
231,
24,
770
]
],
[
[
231,
21,
28768
],
[
28768,
60,
770
]
],
[
[
231,
63,
168
],
[
168,
24,
770
]
],
[
[
231,
1,
1477
],
[
1477,
... | [
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Stavudine",
"{u} (Compound) causes {v} (Side Effect)",
"Acne"
],
[
"Acne",
"{u} (Side Effect) is caused by {v} (... | Stavudine (Compound) causes Acne (Side Effect) and Acne (Side Effect) is caused by Thalidomide (Compound)
Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Stavud... |
DB00612 | DB00912 | 1,121 | 473 | [
"DDInter216",
"DDInter1581"
] | Bisoprolol | Repaglinide | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1121,
24,
473
]
],
[
[
1121,
6,
8374
],
[
8374,
45,
473
]
],
[
[
1121,
21,
30513
],
[
30513,
60,
473
]
],
[
[
1121,
24,
1148
],
[
1148... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Bisoprolol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Bisoprolol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Repaglinide (Compound)
Bisoprolol (Compound) causes Ischaemia (Side Effect) and Ischaemia (Side Effect) is caused by Repaglinide (Compound)
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and ... |
DB08880 | DB08932 | 1,510 | 1,398 | [
"DDInter1771",
"DDInter1111"
] | Teriflunomide | Macitentan | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Major | 2 | [
[
[
1510,
25,
1398
]
],
[
[
1510,
25,
283
],
[
283,
63,
1398
]
],
[
[
1510,
64,
1478
],
[
1478,
24,
1398
]
],
[
[
1510,
63,
597
],
[
597,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macitentan"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
... | Teriflunomide may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Macitentan
Teriflunomide may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate ... |
DB01043 | DB01246 | 108 | 820 | [
"DDInter1146",
"DDInter45"
] | Memantine | Alimemazine | Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in ... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
108,
24,
820
]
],
[
[
108,
63,
104
],
[
104,
40,
820
]
],
[
[
108,
24,
401
],
[
401,
24,
820
]
],
[
[
108,
21,
28662
],
[
28662,
... | [
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Memantine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Memantine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction tha... |
DB00284 | DB00352 | 1,647 | 482 | [
"DDInter11",
"DDInter1814"
] | Acarbose | Tioguanine | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Moderate | 1 | [
[
[
1647,
24,
482
]
],
[
[
1647,
21,
28658
],
[
28658,
60,
482
]
],
[
[
1647,
24,
945
],
[
945,
62,
482
]
],
[
[
1647,
25,
246
],
[
246,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Acarbose",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by ... | Acarbose (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Tioguanine (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Tioguanine
... |
DB00502 | DB01259 | 1,300 | 392 | [
"DDInter853",
"DDInter1024"
] | Haloperidol | Lapatinib | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Major | 2 | [
[
[
1300,
25,
392
]
],
[
[
1300,
6,
4973
],
[
4973,
45,
392
]
],
[
[
1300,
21,
28852
],
[
28852,
60,
392
]
],
[
[
1300,
23,
112
],
[
112,
... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
],
[
[
"Haloperidol",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Lapatini... | Haloperidol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Haloperidol (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Lapatinib (Compound)
Haloperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Me... |
DB00526 | DB06595 | 1,555 | 1,491 | [
"DDInter1355",
"DDInter1214"
] | Oxaliplatin | Midostaurin | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
1555,
24,
1491
]
],
[
[
1555,
24,
112
],
[
112,
23,
1491
]
],
[
[
1555,
23,
1247
],
[
1247,
23,
1491
]
],
[
[
1555,
24,
888
],
[
888,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole... |
DB00215 | DB06081 | 1,230 | 1,046 | [
"DDInter388",
"DDInter286"
] | Citalopram | Caplacizumab | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Moderate | 1 | [
[
[
1230,
24,
1046
]
],
[
[
1230,
25,
1039
],
[
1039,
24,
1046
]
],
[
[
1230,
24,
885
],
[
885,
24,
1046
]
],
[
[
1230,
1,
318
],
[
318,
... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dex... | Citalopram may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epopros... |
DB00468 | DB00862 | 1,424 | 1,005 | [
"DDInter1557",
"DDInter1918"
] | Quinine | Vardenafil | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Moderate | 1 | [
[
[
1424,
24,
1005
]
],
[
[
1424,
6,
8374
],
[
8374,
45,
1005
]
],
[
[
1424,
21,
28658
],
[
28658,
60,
1005
]
],
[
[
1424,
23,
112
],
[
11... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vardenafil"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Quinine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vardenafil (Compound)
Quinine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Vardenafil (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole ... |
DB06817 | DB09322 | 809 | 1,114 | [
"DDInter1563",
"DDInter1966"
] | Raltegravir | Zinc sulfate | Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Major | 2 | [
[
[
809,
25,
1114
]
],
[
[
809,
62,
1220
],
[
1220,
23,
1114
]
],
[
[
809,
25,
1193
],
[
1193,
62,
66
],
[
66,
23,
1114
]
],
[
[
809,
... | [
[
[
"Raltegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Raltegravir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexam... | Raltegravir may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Raltegravir may lead to a major life threatening interaction when taken with Zinc gluconate and Zinc glucon... |
DB00056 | DB00363 | 816 | 695 | [
"DDInter814",
"DDInter419"
] | Gemtuzumab ozogamicin | Clozapine | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Major | 2 | [
[
[
816,
25,
695
]
],
[
[
816,
24,
738
],
[
738,
64,
695
]
],
[
[
816,
63,
305
],
[
305,
25,
695
]
],
[
[
816,
25,
507
],
[
507,
64,... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may lead to a major life threatening interaction when taken with Clozapine
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Esch... |
DB00773 | DB06168 | 896 | 1,531 | [
"DDInter702",
"DDInter281"
] | Etoposide | Canakinumab | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
896,
24,
1531
]
],
[
[
896,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
896,
63,
377
],
[
377,
24,
1531
]
],
[
[
896,
24,
1270
],
[
1270,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin ma... |
DB01218 | DB06595 | 1,493 | 1,491 | [
"DDInter852",
"DDInter1214"
] | Halofantrine | Midostaurin | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
1493,
25,
1491
]
],
[
[
1493,
62,
112
],
[
112,
23,
1491
]
],
[
[
1493,
64,
888
],
[
888,
24,
1491
]
],
[
[
1493,
24,
1017
],
[
1017,
... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Halofantrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Halofantrine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Halofantrine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may c... |
DB00637 | DB00697 | 1,557 | 876 | [
"DDInter128",
"DDInter1821"
] | Astemizole | Tizanidine | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Moderate | 1 | [
[
[
1557,
24,
876
]
],
[
[
1557,
23,
112
],
[
112,
62,
876
]
],
[
[
1557,
24,
401
],
[
401,
63,
876
]
],
[
[
1557,
64,
1424
],
[
1424,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tizanidine
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Pr... |
DB00476 | DB08901 | 109 | 1,468 | [
"DDInter608",
"DDInter1492"
] | Duloxetine | Ponatinib | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
109,
24,
1468
]
],
[
[
109,
24,
478
],
[
478,
24,
1468
]
],
[
[
109,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
109,
18,
3682
],
[
3682,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Duloxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Duloxetine (Compound) ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.